Skip to main content
. 2017 Mar 7;19:42. doi: 10.1186/s13075-017-1250-z

Table 5.

Comparison of demographic, clinical and haemodynamic characteristics of patients with PAH diagnosed at first screen and PAH diagnosed at subsequent screens

Characteristic PAH detected on first screening PAH detected on subsequent screening P value
mean ± SD or % mean ± SD or %
Number of patients 122 38
Age at PAH diagnosis 63.9 ± 11.0 62.7 ± 9.5 0.56
Disease duration at PAH diagnosis 13.4 ± 12.8 14.6 ± 8.7 0.62
Female 96 (85.7%) 32 (84.2%) 0.82
Disease subtype
 Limited 81 (75.7%) 23 (62.2%) 0.03
 Diffuse 17 (15.9%) 13 (35.1%)
 MCTD 9 (8.4%) 1 (2.7%)
Status
 Alive 54 (48.2%) 26 (68.4%) 0.03
 Dead 55 (49.1%) 10 (26.3%)
 Withdrawn 3 (2.7%) 1 (2.6%)
 Unable to contact 0 (0%) 1 (2.6%)
Follow up, years 3.3 ± 2.4 5.9 ± 1.9 <0.001
WHO class at PAH diagnosis
 Class I 4 (4.0%) 0 (0%) 0.01
 Class II 16 (16.2%) 15 (40.5%)
 Class III 63 (75.9%) 20 (54.1%)
 Class IV 16 (16.2%) 2 (5.4%)
6MWD at PAH diagnosis 295.9 ± 118.3 340.6 ± 115.6 0.05
mPAP on RHC 38.2 ± 11.4 32.5 ± 8.3 0.005
mRAP on RHC 9.7 ± 8.5 8.4 ± 3.9 0.40
PVR on RHC 5.5 ± 3.1 3.8 ± 1.7 0.005
CI on RHC 2.9 ± 1.6 2.9 ± 0.7 0.87
Pericardial effusion 16 (16.0%) 1 (2.7%) 0.03

Probability of PAH

PAH pulmonary arterial hypertension, MCTD mixed connective tissue disease, WHO World Health Organisation, 6MWD six-minute walk distance, mPAP mean pulmonary arterial pressure, RHC right-heart catheterization, mRAP mean right atrial pressure, PVR pulmonary vascular resistance, CI cardiac index, NT-pro-BNP N-terminal pro b-type natriuretic peptide